Amgen Board approves a reduction of capital budget to sales operations Friday. We all know what this will mean in the next 12-24 months-- LAYOFFS. Of course they can reduce the market sales but the big costs with sales operations is the salesforce itself. It was a matter of time I guess, with the 1 product company-- only 1 product Enbrel Billion dollars-- going off patent in 2 yrs plus loosing market share fast with Abbott.
Aranesp, Neupogen, Epogen, and Neulasta each do more than $1B/year, dolt. Amgen's Q1 this year did almost $4B. If you'd rather be at Pfizer than Amgen, then you really do have issues.
